Single-Patient Expanded Access Protocol - RNA-LP in a Patient With Recurrent Osteosarcoma

NO_LONGER_AVAILABLE

Conditions studied: Recurrent Osteosarcoma

In brief

Treatment of a patient with recurrent osteosarcoma with personalized pp65/tumor mRNA RNA-LP under an individual patient expanded access protocol.

Key facts

Study ID

NCT07560709

Run by

University of Florida

Last updated by the study team

2026-05-01

Who can join

Age: 15 and older, up to 17. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Participated in clinical trial
• Received pp65 RNA-LPs alone and had pp65/tumor mRNA RNA-LP manufactured
• Progressive disease prior to treatment with pp65/tumor mRNA RNA-LP

You may not qualify if…

• Diagnosis of recurrent OSA is not histopathologically confirmed (i.e. pseudoprogression)

Where it is running

• University of Florida Health — Gainesville, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.